LENVIMA is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC).
LENVIMA: Efficacy that drives results1
Offering more time without disease progression1
-
18.3 month (95% CI: 15.1-NE) median PFS was observed with LENVIMA vs 3.6 months (95% CI: 2.2-3.7) with placebo (HR: 0.21 [95% CI: 0.16-0.28]; P<0.001; primary endpoint)1
- Number of events: 107 (41%) with LENVIMA vs 113 (86%) with placebo
CI=confidence interval; NE=not estimable; PFS=progression-free survival; HR=hazard ratio; AR=adverse reaction.
Not an actual patient